JP2019515033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515033A5 JP2019515033A5 JP2019507069A JP2019507069A JP2019515033A5 JP 2019515033 A5 JP2019515033 A5 JP 2019515033A5 JP 2019507069 A JP2019507069 A JP 2019507069A JP 2019507069 A JP2019507069 A JP 2019507069A JP 2019515033 A5 JP2019515033 A5 JP 2019515033A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- day
- composition according
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 16
- 150000002148 esters Chemical class 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 2
- 208000010796 X-linked adrenoleukodystrophy Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326436P | 2016-04-22 | 2016-04-22 | |
| US62/326,436 | 2016-04-22 | ||
| PCT/US2017/029120 WO2017185087A1 (en) | 2016-04-22 | 2017-04-24 | Use of thyroid beta-agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515033A JP2019515033A (ja) | 2019-06-06 |
| JP2019515033A5 true JP2019515033A5 (cg-RX-API-DMAC7.html) | 2020-06-11 |
| JP6931042B2 JP6931042B2 (ja) | 2021-09-01 |
Family
ID=60116400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019507069A Active JP6931042B2 (ja) | 2016-04-22 | 2017-04-24 | 甲状腺ベータアゴニストの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11351183B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3445373B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6931042B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102407059B1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017252126B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018071586A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3021681C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2992773T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX385085B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017185087A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX385085B (es) | 2016-04-22 | 2025-03-14 | Viking Therapeutics Inc | Uso de beta-agonistas del receptor de la hormona tiroidea. |
| AU2019238090B2 (en) | 2018-03-22 | 2024-08-01 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| JP2007524656A (ja) | 2003-10-23 | 2007-08-30 | セルジーン・コーポレーション | 疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法 |
| CA2546601A1 (en) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| WO2006063128A2 (en) | 2004-12-08 | 2006-06-15 | Sirion Therapeutics, Inc. | Methods, assays and compositions for treating retinol-related diseases |
| US20090232879A1 (en) | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
| US20090028925A1 (en) * | 2005-05-26 | 2009-01-29 | Erion Mark D | Novel Phosphinic Acid-Containing Thyromimetics |
| US20090042857A1 (en) | 2006-02-20 | 2009-02-12 | Masuo Yamaoka | Novel Pharmaceutical |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| WO2011038207A1 (en) * | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| EP3693464A3 (en) | 2011-06-21 | 2020-12-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes |
| WO2014178892A1 (en) | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| MX2017010638A (es) | 2015-02-20 | 2018-05-07 | Univ Oregon Health & Science | Derivados de sobetiroma. |
| WO2017148801A1 (en) | 2016-02-29 | 2017-09-08 | Philip Morris Products S.A. | Hinge-lid container and blank |
| MX385085B (es) | 2016-04-22 | 2025-03-14 | Viking Therapeutics Inc | Uso de beta-agonistas del receptor de la hormona tiroidea. |
| MX2018012904A (es) | 2016-04-22 | 2019-01-31 | Viking Therapeutics Inc | Uso de beta-agonistas del receptor de la hormona tiroidea. |
| KR102331596B1 (ko) | 2016-05-18 | 2021-11-25 | 오레곤 헬스 앤드 사이언스 유니버시티 | 소베티롬의 유도체 |
-
2017
- 2017-04-24 MX MX2018012900A patent/MX385085B/es unknown
- 2017-04-24 AU AU2017252126A patent/AU2017252126B2/en active Active
- 2017-04-24 BR BR112018071586-7A patent/BR112018071586A2/pt not_active Application Discontinuation
- 2017-04-24 US US16/095,228 patent/US11351183B2/en active Active
- 2017-04-24 CA CA3021681A patent/CA3021681C/en active Active
- 2017-04-24 WO PCT/US2017/029120 patent/WO2017185087A1/en not_active Ceased
- 2017-04-24 JP JP2019507069A patent/JP6931042B2/ja active Active
- 2017-04-24 ES ES17786798T patent/ES2992773T3/es active Active
- 2017-04-24 EP EP17786798.3A patent/EP3445373B1/en active Active
- 2017-04-24 KR KR1020187033713A patent/KR102407059B1/ko active Active
-
2022
- 2022-05-06 US US17/738,621 patent/US11951114B2/en active Active
-
2024
- 2024-03-05 US US18/595,919 patent/US12440502B2/en active Active